AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Chimeric Therapeutics partnered with Cell Therapies to explore CAR T manufacturing in Australia.
- The collaboration aims to boost local production of Chimeric’s CAR T assets.
- Chimeric’s COO highlighted improved access to CAR T clinical trials for Australian patients.
- At present, Chimeric has four Phase 1/1b trials open across the United States and is exploring new sites in Australia.
Chimeric Therapeutics (ASX: CHM), an Australian cell therapy firm, has unveiled a new collaboration with Cell Therapies Pty Ltd (CTPL) to explore the feasibility of manufacturing its CAR T assets domestically in Australia. CTPL, based in Australia, -specialises in commercial contract development and manufacturing of cellular immunotherapy products, cell therapy, regenerative medicine, and gene therapy.
“This is great progress for Chimeric and aims to provide Australian patients with access to our first-in-class CAR T clinical trials,” said Dr Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics.
CTPL’s facilities, located within the Peter MacCallum Cancer Centre in Melbourne’s Parkville Precinct, are currently the only biomedical manufacturing site in Australia capable of producing CAR T-cells and other “living” cancer therapies at a commercial scale.
“We are very pleased to work with Chimeric to bring their innovative CAR T products to Australian cancer patients in need,” said Dr Bev Menner, Chief Executive Officer of Cell Therapies.
Chimeric Therapeutics boasts a diversified portfolio of cell therapies, including first-in-class autologous CAR T cell therapies and best-in-class allogeneic NK cell therapies. The company is developing its assets across various oncology indications. Chimeric currently has four Phase 1/1b trials open across the United States and is exploring the addition of new sites in Australia.
The June quarter for Chimeric was marked by advancements in its clinical trials, US patent approval for CHM 0201 (CORE-NK) technology, and the appointment of Dr Rebecca McQualter as Chief Operating Officer.
CHM shares trade higher
The share price of CHM was AU$0.017, up over 6%, at the time of writing on 09 August 2024.
